EKF Diagnostics Holdings PLC Trading update & Expansion of supply agreement (8829T)
30 Marzo 2021 - 12:00AM
UK Regulatory
TIDMEKF
RNS Number : 8829T
EKF Diagnostics Holdings PLC
30 March 2021
This announcement contains inside information
for the purposes of Article 7 of Regulation (EU) No 596/2014 as
it forms part of UK law
by virtue of the European Union (Withdrawal) Act 2018
("MAR")
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Trading update &
Significant expansion of supply agreement for COVID-19 sample
collection kits
Private sector partnership with EKF for global staff testing
programme
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed
point-of-care business, announces that it has signed a new
multi-million dollar global supply contract with its partner from
the private sector. The original agreement with this partner,
announced on 5 August 2020 , covered the supply of COVID-19 sample
collection kits to be used as part of a staff testing programme for
the UK only. The original contract commenced with an initial order
worth GBP3m for the UK, and the Company has received additional
orders approaching a further GBP3m to support the planned global
expansion of the contract.
Under this new multiyear global supply contract, EKF will now
support its partner's world-wide staff testing initiative, with
orders being fulfilled from EKF's production sites in the UK,
Germany and the United States. The Company expects orders from the
expanded agreement to reflect EKF's increased contribution to their
partner's global testing programme, and therefore this agreement is
expected to facilitate future orders which will contribute
materially to 2021 performance and beyond. The contract has an
initial term of two years after which it renews automatically on a
monthly basis.
EKF is supporting its partner's global staff testing initiative,
which aims to offer free, regular COVID-19 testing to its frontline
workforce across all of the many geographies in which it operates.
The programme is designed to identify asymptomatic carriers who
would not have been tested through national testing services, to
detect the virus earlier before it spreads.
Further to the announcement on 12 January 2021 , trading in the
first quarter was materially ahead of management expectations. With
subsequent orders under this expanded global contract expected to
make a considerable contribution throughout the current financial
year and beyond, the Board is confident that trading for the year
ending 31 December 2021 will be significantly ahead of already
upgraded management expectations.
Julian Baines, CEO of EKF, said: "We are delighted to continue
our relationship with our partner in the private sector and support
their global staff testing initiative with the expansion of our
supply agreement for collection kits. The contract has gone from
covering the UK to supporting our partner's global staff testing
programme. We expect this partnership to contribute materially to
our 2021 performance and are confident in delivering results
significantly ahead of current management forecasts which were most
recently upgraded in January this year."
The persons responsible for arranging the release of this
Announcement on behalf of the Company
are Julian Baines, CEO, and Richard Evans, FD and COO
respectively.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman Tel: +44 (0) 29 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer Tel: 020 7496 3000
Aubrey Powell / George Tzimas / Tom
Salvesen
Walbrook PR Limited Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0) 7980 541 893 / +44 (0) 7584
391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading point-of-care diagnostics and central
laboratory assay manufacturer with an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analysers in regular use
across more than 100 countries. EKF specialises in developing tests
for use in anemia and diabetes diagnosis and management, as well as
providing a portfolio of reagents for use in clinical chemistry
analysers.
EKF specialises in the development, production and worldwide
distribution of point-of-care analyzers and clinical chemistry
reagents for use in hospital and research laboratories, doctor's
offices, blood banks and for in-field anaemia screening programmes.
EKF is also a bulk manufacturer of enzymes and has custom
manufacturing facilities in the USA for a variety of life science
products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDDGDXSGDDGBC
(END) Dow Jones Newswires
March 30, 2021 02:00 ET (06:00 GMT)
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024